TAM
IOVA icon

Tiverton Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Tiverton Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$76K Sell
4,162
-596
-13% -$13.2K ﹤0.01% 667
2019
Q2 		$117K Hold
4,758
– – ﹤0.01% 606
2019
Q1 		$45K Sell
4,758
-510
-10% -$4.95K ﹤0.01% 634
2018
Q4 		$47K Buy
+5,268
New +$50.8K ﹤0.01% 457

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tiverton Asset Management's IOVA Position: Q3 2019 in Review

Tiverton Asset Management reduced its Iovance Biotherapeutics (IOVA) stake by 13% in Q3 2019, selling an estimated $13.2K and leaving 4,162 shares worth $76K. The position accounts for ﹤0.01% of the portfolio, ranked #667.

Tiverton Asset Management first reported a position in IOVA in Q4 2018 and has held it in 4 quarters since. The position peaked at $117K in Q2 2019. 173 funds tracked by Wall St. Rank hold IOVA as of Q3 2019.

  • Tiverton Asset Management held 4,162 shares of Iovance Biotherapeutics worth $76K as of Q3 2019.
  • Tiverton Asset Management sold 596 Iovance Biotherapeutics shares in Q3 2019, an estimated $13.2K.
  • Iovance Biotherapeutics made up ﹤0.01% of Tiverton Asset Management's portfolio in Q3 2019, its #667 holding.
  • Tiverton Asset Management first reported a position in Iovance Biotherapeutics in Q4 2018 and has held it in 4 quarters since.
  • Tiverton Asset Management's Iovance Biotherapeutics position peaked at $117K in Q2 2019.
  • 173 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.